Nedosiran Dosage
Medically reviewed by Drugs.com. Last updated on Mar 29, 2024.
Applies to the following strengths: 160 mg/mL; 128 mg/0.8 mL; 80 mg/0.5 mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Primary Hyperoxaluria
Body Weight greater than or equal to 50 kg: 160 mg subcutaneously once monthly
Body Weight less than 50 kg: 128 mg subcutaneously once monthly
Use: To lower urinary oxalate in patients with primary hyperoxaluria type 1 and relatively preserved kidney function (eGFR over or equal to 30 mL/min/1.73 m2)
Usual Pediatric Dose for Primary Hyperoxaluria
Children 9 to 11 years old:
Body Weight greater than or equal to 50 kg: 160 mg subcutaneously once monthly
Body Weight less than 50 kg: 3.3 mg/kg subcutaneously once monthly, not to exceed 128 mg (vial, dose volume rounded to nearest 0.1 mL)
Children 12 years and older:
Body Weight greater than or equal to 50 kg: 160 mg subcutaneously once monthly
Body Weight less than 50 kg: 128 mg subcutaneously once monthly
Use: To lower urinary oxalate in children 9 years of age or older with primary hyperoxaluria type 1 and relatively preserved kidney function (eGFR over or equal to 30 mL/min/1.73 m2)
Renal Dose Adjustments
Mild and Moderate Renal Dysfunction: No adjustment recommended.
Severe Renal Dysfunction: Data not available
Liver Dose Adjustments
Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 9 years.
Dialysis
Data not available
Other Comments
Administration advice:
- Dosing is based on actual body weight.
- If a planned dose is missed, administer as soon as possible. If the dose has been missed for more than 7 days, administer as soon as possible, and resume monthly dosing from the most recently administered dose.
- Patients 12 years and older may inject their dose using the pre-filled syringes. In patients younger than 12, administration by a healthcare professional or caregiver is recommended.
- Administer by subcutaneous injection in the abdomen, at least 2 inches from the navel, or the upper thigh. Do not inject into a vein or into scarred or bruised skin.
- Read the US FDA-approved patient labeling for further administration instructions.
Storage requirements:
- Store refrigerated at 2C to 8C (36F to 46F)
- If needed, it can be stored at 15C to 30C (59F to 86F) for a maximum of 28 days. Do not freeze.
- Store in the original carton, away from direct heat and light.
Patient advice:
- Read the Patient Information and Instructions for Use.
More about nedosiran
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Rivfloza
Rivfloza (nedosiran) is a medication used to treat primary hyperoxaluria type 1 (PH1) that works to ...
Aqneursa
Aqneursa information from Drugs.com, includes Aqneursa side effects, interactions and indications.
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Cerdelga
Cerdelga (eliglustat) is used to treat mild to moderate Type 1 Gaucher Disease. Includes Cerdelga ...
Crysvita
Crysvita is used for familial hypophosphatemia, osteomalacia, X-Linked Hypophosphatemia
Galafold
Galafold (migalastat) is used to treat Fabry disease. Includes Galafold side effects, interactions ...
Givlaari
Givlaari injection is used for acute hepatic porphyria (AHP) to reduce the number of acute attacks ...
Iqirvo
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in combination with ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.